Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV Virions
|
|
- Anthony Austin
- 6 years ago
- Views:
Transcription
1 JOURNAL OF VIROLOGY, Jan. 2007, p Vol. 81, No X/07/$ doi: /jvi Copyright 2007, American Society for Microbiology. All Rights Reserved. Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV Virions Zhen-Yong Keck, 1 Jinming Xia, 1 Zhaohui Cai, 2 Ta-Kai Li, 1 Ania M. Owsianka, 3 Arvind H. Patel, 3 Guangxiang Luo, 2 and Steven K. H. Foung 1 * Department of Pathology, Stanford University School of Medicine, Stanford, California ; Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky ; and MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, United Kingdom 3 Received 8 August 2006/Accepted 23 October 2006 Development of full-length hepatitis C virus (HCV) RNAs replicating efficiently and producing infectious cell-cultured virions, HCVcc, in hepatoma cells provides an opportunity to characterize immunogenic domains on viral envelope proteins involved in entry into target cells. A panel of immunoglobulin G1 human monoclonal antibodies (HMAbs) to three immunogenic conformational domains (designated A, B, and C) on HCV E2 glycoprotein showed that epitopes within two domains, B and C, mediated HCVcc neutralization, whereas HMAbs to domain A were all nonneutralizing. For the neutralizing antibodies to domain B (with some to conserved epitopes among different HCV genotypes), the inhibitory antibody concentration reducing HCVcc infection by 90%, IC 90, ranged from 0.1 to 4 g/ml. For some neutralizing HMAbs, HCVcc neutralization displayed a linear correlation with an antibody concentration between the IC 50 and the IC 90 while others showed a nonlinear correlation. The differences between IC 50 /IC 90 ratios and earlier findings that neutralizing HMAbs block E2 interaction with CD81 suggest that these antibodies block different facets of virus-receptor interaction. Collectively, these findings support an immunogenic model of HCV E2 having three immunogenic domains with distinct structures and functions and provide added support for the idea that CD81 is required for virus entry. Hepatitis C virus (HCV) is a positive-stranded RNA virus containing at least three structural proteins core and two envelope glycoproteins, E1 and E2 and six nonstructural proteins (1). Studies with infectious retroviral particles pseudotyped with HCV E1E2 (HCVpp) showed that virus entry requires both E1 and E2 glycoproteins associated as a heterodimer, involves interactions with CD81, is low ph dependent, and is blocked by antibodies to HCV E2 and sera from HCV-infected individuals (3, 8, 13). Detailed information on the immunogenic and functional organization of HCV envelope glycoproteins and in particular E2 is needed to facilitate immunotherapeutics and vaccine development. Cross-competition studies with a panel of HCV E2 human monoclonal antibodies (HMAbs) showed that the HCVpp E2 glycoprotein contains three immunogenic conformational domains, designated A, B, and C, that are accessible on the surface of HCVpp (10). Each domain carries epitopes that are either highly conserved among diverse HCV genotypes or more restrictedly conserved. Epitopes within two domains, B and C, are targets of HCVpp-neutralizing antibodies, and the other domain, A, contains nonneutralizing epitopes that participate in structural changes as part of a ph-dependent virus envelope fusion process (9). Recently, three groups developed full-length HCV RNA genomes replicating efficiently when transfected into human hepatoma cells (Huh7) and producing infectious virions (11, 15, 17). The availability of these and other cell-cultured * Corresponding author. Mailing address: Stanford Medical School Blood Center, 800 Welch Rd., Palo Alto, CA Phone: (650) Fax: (650) sfoung@stanford.edu. Published ahead of print on 1 November infectious HCV virions, HCVcc, should greatly accelerate studies of HCV biology (4, 11, 14 17). This report focuses on the immunogenic and functional organization of HCV E2 on HCVcc virions. Three immunogenic conformational domains on HCV virion. It has been reported elsewhere that stable human hepatoma cell lines containing a chromosomally integrated cdna of HCV genotype 2a (JFH1) RNA constitutively secrete infectious virions into the medium (4). This provides a robust source of virus to study each aspect of the entire HCV life cycle. HCVcc virions from stable cell lines could reinfect naïve Huh7.5 cells, and viral replication could be suppressed by alpha interferon. We examined whether HCVcc infectivity can be neutralized by a panel of immunoglobulin G1 (IgG1) HMAbs to three distinct immunogenic domains on HCV E2 glycoprotein. Four antibodies (CBH-2, -5, -8C, and -11) to domain B, three antibodies (CBH-4B, -4D, and -4G) to domain A, one antibody to domain C (CBH-7), and a negativecontrol isotype-matched HMAb to cytomegalovirus (R04) were tested. Production of HCVcc, titration of infectious units, and HCV infection assays were performed as described previously (4). To determine HCV-neutralizing activities of HMAbs, HCVcc-containing culture medium (HCV titer, IU/ml) was used to dilute HMAbs to different concentrations and then added to Huh7.5 cells in a 12-well cell culture plate. After 3hof incubation, the HCV and antibody mixture was removed, and the cells were washed twice with phosphate-buffered saline (PBS) and incubated with 1 ml Dulbecco modified Eagle medium containing 10% fetal bovine serum. Infectivity was determined by measuring the levels of positive-stranded HCV RNA using an RNase protection assay (RPA) (4). Some of the antibodies 1043
2 1044 NOTES J. VIROL. FIG. 1. Neutralization of genotype 2a HCVcc infectivity as determined by RPA using [ - 32 P]UTP-labeled HCV-specific RNA probes. HCVcc were incubated with anti-e2 HMAbs at increasing concentrations prior to infection of Huh7.5 cells preseeded in a six-well plate. Antibody concentrations used were 0, 0.016, 0.08, 0.4, and 2.0 g/ml for CBH-2, -5, and -8C; 0.08, 0.4, 2, and 10 g/ml for CBH-11; and 0, 0.4, 2, 10, and 50 g/ml for CBH-7, -4G, -4B, -4D, and R04 (an isotype-matched HMAb to a cytomegalovirus epitope), respectively. At 3 h p.i., the HCVantibody-containing medium was removed, and the cells were washed with PBS, refed with fresh medium, and incubated at 37 C. At 72 h p.i., total RNA was extracted from the HCV-infected Huh7.5 cells using Trizol reagent (Invitrogen). The presence of positive-strand HCV RNA in the HCV-infected Huh7.5 cells was determined by RPA using an RPA III kit following the manufacturer s procedures (Ambion). As described previously (4), a total of 10 g of total cellular RNA extracted from HCV-infected Huh7.5 cells was hybridized with 10 5 cpm of the [ 32 P]UTPlabeled negative-strand 3 -untranslated-region RNA probe and cpm of human -actin RNA probe. After RNase digestion, the RNA products were analyzed in a 6% polyacrylamide-7.7 M urea gel, autoradiographed, and quantified with a phosphorimager. Probes for HCV and -actin (P hcv and P actin ) are indicated on the right. Numbers at left are molecular sizes in base pairs. (CBH-7, -4G, -4B, and -4D and control antibody R04) were assessed at concentrations up to 50 g/ml. The total cellular RNA was extracted from the HCV-infected Huh7.5 cells in six-well cell culture plates at 3 days postinfection (p.i.) and quantified by an RPA using an [ - 32 P]UTP-labeled RNA probe containing the negative-stranded HCV 3 -untranslatedregion RNA (Fig. 1). The HMAbs to domain B, CBH-2, -5, -8C, and -11, neutralized HCVcc infectivity with high potency, while antibodies to domain A, CBH-4G, -4B, and -4D, had no neutralizing activities. The HMAb to domain C, CBH-7, showed a modest HCVcc-neutralizing activity. HCVcc neutralization was confirmed with NS3 protein expression measurements by Western blot analysis. Huh7.5 cells were infected in the presence of each of the antibodies as described above; cells were lysed at 3 days p.i. and analyzed. The abilities of each domain A and representative domain B (CBH-5) and domain C (CBH-7) HMAbs to neutralize HCV infectivity to Huh7.5 cells are shown in Fig. 2A and B. All domain A HMAbs showed no effect on NS3 protein levels (Fig. 2A). Strikingly, HCVcc was completely neutralized at low antibody concentrations by all domain B HMAbs as represented by CBH-5 in Fig. 2B and more fully discussed below. However, the domain C HMAb, CBH-7, showed neutralizing activity only at an IgG concentration of 5 g/ml (Fig. 2B). The glyceraldehyde-3- phosphate dehydrogenase (GAPDH) protein used as an internal control was detected by using an anti-gapdh monoclonal antibody in Fig. 2A and B (Abcam, Cambridge, MA). To determine whether a reduction in HCV RNA and NS3 expression by neutralizing antibodies is correlated with a reduction in infectious virion production, CBH-4G and CBH-5 as respective representatives of domains A and B HMAbs were assessed in an infectivity reduction assay (Table 1). HCVcc were incubated with each HCV HMAb and R04 (control) at 0.1 to 100 g/ml for 1 hour prior to Huh7.5 cell infection. Huh7.5 cells were preseeded the previous day at a density of 32,000 cells/well in a 24-well plate. At 3 h p.i., HCV-containing medium was replaced with 1 ml of Dulbecco modified Eagle medium containing 10% fetal calf serum. At day 3 p.i., 1 ml of supernatant from each well was centrifuged at 1,000 g for 5 min to remove cell debris and 350 l was then added to a second corresponding well containing uninfected Huh7.5 cells. Following another 3 days, cell culture medium was removed. The cells were harvested and fixed in triplicate sets onto a 24-spot Teflon-coated microscope slide as described previously (7). Infection was assessed for NS3, NS5A, and E2 expression by an indirect immunofluorescence assay as described previously (7), employing a mouse monoclonal antibody to NS3 (4), a polyclonal sheep anti-ns5a serum (12), and antibody CBH-2 to E2. Detection was with fluorescein isothiocyanate-conjugated anti-species IgG (Jackson ImmunoResearch Laboratories), and counterstaining was done with Evans blue. Bound antibody was revealed by fluorescence microscopy. At all tested antibody concentrations for CBH-4G and R04, the HCVcc yield in the first set of infected cells was not reduced, as sufficient amounts of virus were passed to the second set of Huh7.5 cells, leading to the majority of the cells being infected. For CBH-5, reduced HCVcc infection was observed starting at 0.5 to 1 g/ml, with complete infectivity reduction at concentrations above 1 g/ml. Collectively, these findings support an immunogenic model of HCVcc E2 containing three distinct functional domains as previously shown with HCVpp studies. Virus neutralization potency with HCV virions. A more quantitative measure of neutralization potency was determined by calculating IC 90, the inhibitory antibody concentration reducing HCV infection by 90% (Fig. 2B and C). HCVcc virions were incubated for 2 h with each HMAb at to 100 g/ml prior to Huh7.5 cell infection. Figure 2B shows representative antibodies, with CBH-5 blocking NS3 expression at 0.02 g/ml but CBH-7 requiring 10 g/ml. NS3 reduction as quantified by phosphorimager analysis for each HMAb is summarized in Fig. 2C. The four antibodies to domain B, CBH-2, -5, -8C, and -11, completely neutralized HCVcc with respective IC 90 s at 0.4, 0.1, 1, and 4 g/ml. The average Ig concentration of domain B HMAbs for the IC 90 was 1.37 g/ml or 9.14 nmol/liter. For domain C HMAb CBH-7, the IC 90 was at 50 g/ml or 332 nmol/liter. The neutralization potency is in the order CBH-5 CBH-2 CBH-8C CBH-11 CBH-7, which is in agreement with HCVpp pseudotyped with JFH1 2a E1E2, with domain B HMAbs having greater activities than domain C-specific CBH-7 (Fig. 3A and B).
3 VOL. 81, 2007 NOTES 1045 FIG. 2. Effect of HMAbs on genotype 2a HCVcc infectivity as determined by NS3 expression. HCVcc were incubated with each HMAb at increasing concentrations prior to infection of Huh7.5 cells preseeded in a 24-well plate. At 3 h p.i., the HCVcc-antibody-containing medium was removed, and the cells were washed twice with PBS followed by incubation at 37 C in fresh medium. Cells were harvested for Western blotting analysis at 72 h p.i. (A) Domain A HMAbs showed no reduction of NS3 expression. (B) Quantitative HCVcc virus neutralization with CBH-5 and -7 shown as respective representative domain B and C antibodies. HCV NS3 protein expression was determined by a monoclonal antibody specific to NS3 (4). The GAPDH protein used as an internal control was detected using an anti-gapdh monoclonal antibody (Abcam). The expression level for NS3 protein was quantified by phosphorimager analysis, and the percent neutralization relative to control cells without antibody treatment (100%) was calculated. (C) Table of CBH-2, -5, -8C, -11, and -7 antibody concentrations to reach 50% and 90% HCVcc neutralization, IC 50 and IC 90, respectively, as calculated using Prism software (GraphPad). Although these HCV HMAbs were derived from a genotype 1b-infected donor, the IC 50 s of domain B HMAbs for 2a strain JFH1 were lower than with genotype 1b E1E2-pseudotyped HCVpp (Fig. 3B). Also, these antibodies were not able to TABLE 1. HCV infectivity reduction Infection level at antibody concn ( g/ml) a : Antibody CBH-4G CBH-5 / R04 a, 60% infected cells;, 50% infected cells; /, 20% infected cells;, 0.5% infected cells. completely neutralize 1b HCVpp (9, 13) in contrast to complete 2a HCVpp neutralization. Maximum neutralization of genotype 1b HCVpp ranged between 50 and 85% at a saturating IgG concentration of 50 g/ml or higher as shown in Fig. 3A. The IC 50 s for 1b HCVpp neutralization for CBH-2, -5, -8C, -11, and -7 were 1.33, 1.77, 34.58, 16.74, and g/ml, respectively. The respective IC 50 s for JFH1 2a HCVpp neutralization for CBH-2, -5, -8C, -11, and -7 were 0.35, 0.10, 1.50, 1.50, and 60 g/ml. This genotypic difference cannot be explained by antibody affinity, as the antibody disassociation constant, K D, is similar for each antibody with both genotypes except for CBH-8C (Fig. 3C). Studies are under way to assess the relative density of each epitope as identified by these HMAbs on the surface of both genotype 1b and 2a HCVpp, as
4 1046 NOTES J. VIROL. FIG. 3. Virus neutralization of genotype 2a and 1b HCVpp. HCVpp production, purification, and neutralization were performed as previously described (2, 9). (A) HCVpp were incubated with each E2 HMAb at increasing concentrations (0, 0.01, 0.1, 1, 5, 10, 20, 50, and 100 g/ml) for 60 min at 37 C prior to infection of Huh7 cells preseeded in a 96-well plate. At 3 h p.i., the HCVcc-antibody-containing medium was removed, and the cells were washed twice with PBS. Samples were harvested for luciferase activities assay at 72 h p.i. Neutralization activity was determined by percent reduction of luciferase activity relative to no-antibody control. (B) IC 50 s of CBH-2, -5, -8C, -11, and -7 HMAbs for genotype 2a or 1b HCVpp as calculated using Prism software (GraphPad). (C) Antibody K D measurements were performed with sucrose density equilibrium gradient-purified genotype 1b and JFH1 2a HCVpp as previously described (9). the critical number of binding sites being occupied is another contributing factor for virus neutralization. The IC 50 of these antibodies for either 1b or JFH1 2a HCVpp (Fig. 3B) was higher than that for JFH1 2a HCVcc (Fig. 2C). The basis for the global differences between HCVcc and HCVpp is not known but could reflect differences in how these particles are assembled, leading to differences in the relative copy number of the incorporated viral glycoproteins and in amino acid alignment and altered accessibility of these epitopes. This could include differences in E2 glycosylation with HCVpp and HCVcc affecting the surface exposure of their epitopes. Lending support to differences in how these particles are packaged are earlier studies with CD81, a putative HCV receptor (6). All domain B (CBH-2, -5, -8C, and -11) and C (CBH-7) antibodies blocked recombinant E2 protein binding to CD81-expressing cells or to CD81-coated plates and were designated as neutralization-of-binding (NOB) positives. All antibodies to domain A, CBH-4B, -4D, and -4G, were NOB negative as they failed to block E2-CD81 interaction. While an antibody designated NOB positive or negative was generally predictive of HCVpp and HCVcc neutralization, there are subtle differences. CBH-7 blocks recombinant 1a E2 binding to CD81 and neutralizes 1a HCVpp but did not block 1a plasma-derived HCV virion binding to CD81 (6). While multiple factors can account for a lack of binding to plasmaderived virions, if HCVcc is more structurally similar to plasmaderived virions than HCVpp is, the findings with CBH-7 are consistent with the view that the structural arrangement of envelope glycoproteins is different with HCVpp and HCVcc and certainly with the CBH-7 epitope. Another observation was the HCVcc neutralization profiles for CBH-5 and CBH-7 displaying a linear relationship with antibody concentration from IC 50 to IC 90 (Fig. 2B and C). However, the profiles for CBH-2, -8C, and -11 displayed a nonlinear relationship between IC 50 and IC 90, in which 5 to 14 times more antibodies were required to achieve IC 90 than IC 50. The possible contributions to differences with neutralization profiles include affinity of antibody binding to different viral epitopes, kinetics of antibody association and dissociation with targeted antigen, IgG subclass, and mechanisms of neutralization whereby these antibodies inhibit different facets of HCVcc interaction with its putative receptor(s) (5). However, IgG subclass or antibody affinity is an unlikely factor in this case as these antibodies are all IgG1 and their relative K D values are similar apart from CBH-5 (Fig. 3C). More studies will be required to find out whether these antibodies block at distinct steps in virus-receptor interactions. In summary, the immunogenic organization of HCVcc E2 glycoprotein consists of three distinct domains with epitopes mediating virus neutralization restricted to two domains as described for HCVpp. The fact
5 VOL. 81, 2007 NOTES 1047 that the ability to block E2 binding to CD81 is predictive of neutralization provides additional support for the idea that CD81 is a required molecule for HCVpp and HCVcc entry. We are grateful to Charles Rice, Rockefeller University, for providing the Huh7.5 cells; Mark Harris, University of Leeds, for the sheep anti-ns5a serum; and Neil Greenspan, Case Western Reserve University, for helpful discussion, and we appreciate the technical assistance of H. Y. Chen and Dana Bangs. This work was supported in part by National Institutes of Health grants HL and AI47355 to S.K.H.F. and CA93712 to G.L. and by the Medical Research Council, United Kingdom. REFERENCES 1. Bartenschlager, R Hepatitis C virus molecular clones: from cdna to infectious virus particles in cell culture. Curr. Opin. Microbiol. 9: Bartosch, B., J. Dubuisson, and F. L. Cosset Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197: Bartosch, B., A. Vitelli, C. Granier, C. Goujon, J. Dubuisson, S. Pascale, E. Scarselli, R. Cortese, A. Nicosia, and F. L. Cosset Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278: Cai, Z., C. Zhang, K. S. Chang, J. Jiang, B. C. Ahn, T. Wakita, T. J. Liang, and G. Luo Robust production of infectious hepatitis C virus (HCV) from stably HCV cdna-transfected human hepatoma cells. J. Virol. 79: Greenspan, N. S Affinity, complementarity, cooperativity, and specificity in antibody recognition. Curr. Top. Microbiol. Immunol. 260: Hadlock, K. G., R. E. Lanford, S. Perkins, J. Rowe, Q. Yang, S. Levy, P. Pileri, S. Abrignani, and S. K. Foung Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74: Hadlock, K. G., J. Rowe, S. Perkins, P. Bradshaw, G. Y. Song, C. Cheng, J. Yang, R. Gascon, J. Halmos, S. M. Rehman, M. S. McGrath, and S. K. Foung Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J. Virol. 71: Hsu, M., J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C. M. Rice, and J. A. McKeating Hepatitis C virus glycoproteins mediate ph-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA 100: Keck, Z. Y., T. K. Li, J. Xia, B. Bartosch, F. L. Cosset, J. Dubuisson, and S. K. Foung Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J. Virol. 79: Keck, Z. Y., A. Op De Beeck, K. G. Hadlock, J. Xia, T. K. Li, J. Dubuisson, and S. K. Foung Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78: Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice Complete replication of hepatitis C virus in cell culture. Science 309: Macdonald, A., K. Crowder, A. Street, C. McCormick, K. Saksela, and M. Harris The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-erk pathway signaling. J. Biol. Chem. 278: Op De Beeck, A., C. Voisset, B. Bartosch, Y. Ciczora, L. Cocquerel, Z. Keck, S. Foung, F. L. Cosset, and J. Dubuisson Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 78: Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F. L. Cosset, and R. Bartenschlager Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 103: Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. J. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11: Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. USA 103: Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102:
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein
Journal of General Virology (2008), 89, 653 659 DOI 10.1099/vir.0.83386-0 Short Communication Correspondence Arvind H. Patel a.patel@mrcvu.gla.ac.uk Broadly neutralizing human monoclonal antibodies to
More informationRobust Production of Infectious Hepatitis C Virus (HCV) from Stably HCV cdna-transfected Human Hepatoma Cells
JOURNAL OF VIROLOGY, Nov. 2005, p. 13963 13973 Vol. 79, No. 22 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.22.13963 13973.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Robust
More informationProduction of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures
JOURNAL OF VIROLOGY, May 2007, p. 4405 4411 Vol. 81, No. 9 0022-538X/07/$08.00 0 doi:10.1128/jvi.02334-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Production of Infectious
More informationHepatitis C virus (HCV), a member of the Flaviviridae
GASTROENTEROLOGY 2008;135:1719 1728 Neutralizing Host Responses in Hepatitis C Virus Infection Target Viral Entry at Postbinding Steps and Membrane Fusion ANITA HABERSTROH,*, EVA K. SCHNOBER,*,, MIRJAM
More informationProduction of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells MinKyung Yi*, Rodrigo A. Villanueva*, David L. Thomas, Takaji Wakita, and Stanley M. Lemon* *Center
More informationDomain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles
Journal of General Virology (2009), 90, 1329 1334 DOI 10.1099/vir.0.009332-0 Short Communication Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles Mair
More informationThe Tight Junction Proteins Claudin-1, -6, and -9 Are Entry Cofactors for Hepatitis C Virus
JOURNAL OF VIROLOGY, Apr. 2008, p. 3555 3560 Vol. 82, No. 7 0022-538X/08/$08.00 0 doi:10.1128/jvi.01977-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. The Tight Junction Proteins
More informationHepG2 Cells Expressing MicroRNA mir-122 Support the Entire Hepatitis C Virus Life Cycle
JOURNAL OF VIROLOGY, Nov. 2011, p. 12087 12092 Vol. 85, No. 22 0022-538X/11/$12.00 doi:10.1128/jvi.05843-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. HepG2 Cells Expressing
More informationThe Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein
JOURNAL OF VIROLOGY, Aug. 2007, p. 8101 8111 Vol. 81, No. 15 0022-538X/07/$08.00 0 doi:10.1128/jvi.00127-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. The Neutralizing Activity
More informationThe role of neutralizing antibodies in hepatitis C virus infection
Journal of General Virology (2012), 93, 1 19 DOI 10.1099/vir.0.035956-0 Review The role of neutralizing antibodies in hepatitis C virus infection Victoria C. Edwards, Alexander W. Tarr, Richard A. Urbanowicz
More informationHepatitis C virus (HCV) has emerged as the major ORIGINAL ARTICLES
ORIGINAL ARTICLES VIRAL HEPATITIS Hepatitis C Virus Cell-Cell Transmission in Hepatoma Cells in the Presence of Neutralizing Antibodies Jennifer M. Timpe, 1 Zania Stamataki, 1 Adam Jennings, 1 Ke Hu, 1
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationsirna a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle
Author manuscript, published in "Journal of Hepatology 2008;48(3):523-5" DOI : 10.1016/j.jhep.2007.12.007 Journal of Hepatology: Journal Club sirna a powerful tool to unravel hepatitis C virus-host interactions
More informationPermissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection
Journal of General Virology (215), 96, 1369 1373 DOI 1.199/vir..85 Short Communication Correspondence Jane A. McKeating j.a.mckeating@bham.ac.uk Permissivity of primary hepatocytes and hepatoma cell lines
More informationHED is supported by NH&MRC senior research fellowship
Manuscript title: Antibodies to the high density lipoprotein receptor SR-B1 potently inhibit hepatitis C virus replication in vivo: New avenues for preventing reinfection of the liver following transplantation.
More informationScavenger Receptor Class B Type I Is a Key Host Factor for Hepatitis C Virus Infection Required for an Entry Step Closely Linked to CD81
Scavenger Receptor Class B Type I Is a Key Host Factor for Hepatitis C Virus Infection Required for an Entry Step Closely Linked to CD81 Mirjam B. Zeisel, 1-3 George Koutsoudakis, 4 Eva K. Schnober, 1-3,5
More informationTSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet
Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 TSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet Details
More informationReceived 24 July 2008/Accepted 25 September 2008
JOURNAL OF VIROLOGY, Dec. 2008, p. 12020 12029 Vol. 82, No. 24 0022-538X/08/$08.00 0 doi:10.1128/jvi.01569-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Identification of a
More informationIdentification of IFN-alpha Induced Envelope Mutations of Hepatitis C Virus In Vitro Associated
JVI Accepts, published online ahead of print on 18 September 2013 J. Virol. doi:10.1128/jvi.00901-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Serre et al., September
More informationCyclophilin A Interacts with Domain II of Hepatitis C Virus NS5A and Stimulates RNA Binding in an Isomerase-Dependent Manner
JOURNAL OF VIROLOGY, July 2011, p. 7460 7464 Vol. 85, No. 14 0022-538X/11/$12.00 doi:10.1128/jvi.00393-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Cyclophilin A Interacts
More informationEffects of Mutations of the Initiation Nucleotides on Hepatitis C Virus RNA Replication in the Cell
JOURNAL OF VIROLOGY, Apr. 2004, p. 3633 3643 Vol. 78, No. 7 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.7.3633 3643.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Effects of
More informationHIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates
HIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
More informationEfficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells
Journal of General Virology (2009), 90, 1681 1691 DOI 10.1099/vir.0.010983-0 Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells Yasuaki Bungyoku, Ikuo
More informationHepatitis C virus (HCV) infection is a major public health burden
Identification of Alpha Interferon-Induced Envelope Mutations of Hepatitis C Virus In Vitro Associated with Increased Viral Fitness and Interferon Resistance Stéphanie B. N. Serre, a Henrik B. Krarup,
More informationSupplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR
Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4
More informationReceived 5 November 2010/Accepted 6 December 2010
JOURNAL OF VIROLOGY, Mar. 2011, p. 2138 2147 Vol. 85, No. 5 0022-538X/11/$12.00 doi:10.1128/jvi.02313-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Production of Hepatitis
More informationDiverse CD81 Proteins Support Hepatitis C Virus Infection
JOURNAL OF VIROLOGY, Nov. 2006, p. 11331 11342 Vol. 80, No. 22 0022-538X/06/$08.00 0 doi:10.1128/jvi.00104-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Diverse CD81 Proteins
More informationGlobally, an estimated 160 million people are
Incorporation of Primary Patient-Derived Glycoproteins Into Authentic Infectious Hepatitis C Virus Particles Juliane Doerrbecker, 1 Martina Friesland, 1 Nina Riebesehl, 1 Corinne Ginkel, 1 Patrick Behrendt,
More informationNOTE. Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes
JOURNAL OF VIROLOGY, May 2006, p. 4633 4639 Vol. 80, No. 9 0022-538X/06/$08.00 0 doi:10.1128/jvi.80.9.4633 4639.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. NOTE Generation
More informationHepatitis C virus (HCV) is a highly variable, Isolate-Dependent Use of Claudins for Cell Entry by Hepatitis C Virus VIRAL HEPATITIS
VIRAL HEPATITIS Isolate-Dependent Use of Claudins for Cell Entry by Hepatitis C Virus Sibylle Haid, 1 Christina Grethe, 1 Michael T. Dill, 2 Markus Heim, 2 Lars Kaderali, 3 and Thomas Pietschmann 1 Hepatitis
More informationCharacterization of hepatitis C virus intra- and inter-genotypic chimeras reveals a role of. the glycoproteins in virus envelopment.
JVI Accepts, published online ahead of print on 2 October 2013 J. Virol. doi:10.1128/jvi.01708-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Characterization of hepatitis
More informationSupplementary data Supplementary Figure 1 Supplementary Figure 2
Supplementary data Supplementary Figure 1 SPHK1 sirna increases RANKL-induced osteoclastogenesis in RAW264.7 cell culture. (A) RAW264.7 cells were transfected with oligocassettes containing SPHK1 sirna
More informationObjective 3. Develop new and improved diagnostic tools, vaccines, and novel management approaches
Objective 3. Develop new and improved diagnostic tools, vaccines, and novel management approaches Development of novel nanoparticle-base vaccines for infectious bronchitis PI, Mazhar I. Khan; CoPI, Peter
More informationThis is the author s final accepted version.
Cowton, V. M., Angus, A. G.N., Cole, S. J., Markopoulou, C. K., Owsianka, A., Dunlop, J. I., Gardner, D., Krey, T., and Patel, A. H. (2016) Role of conserved E2 residue W420 in receptor binding and hepatitis
More informationMaterials and Methods , The two-hybrid principle.
The enzymatic activity of an unknown protein which cleaves the phosphodiester bond between the tyrosine residue of a viral protein and the 5 terminus of the picornavirus RNA Introduction Every day there
More informationData Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538
Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538 Background: TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationDownloaded by on April 28, 2018 https://pubs.acs.org Publication Date: April 24, 1984 doi: /bk
1 Virus-Receptor Interactions BERNARD N. FIELDS Department of Microbiology and Molecular Genetics, Harvard Medical School, and Department of Medicine (Infectious Disease), Brigham and Women's Hospital,
More informationSIV p27 ANTIGEN CAPTURE ASSAY
SIV p27 ANTIGEN CAPTURE ASSAY Enzyme Immunoassay for the detection of Simian Immunodeficiency Virus (SIV) p27 in tissue culture media Catalog #5436 and #5450 Version 6; 12/2012 ABL PRODUCTS AND SERVICES
More informationRecombinant Protein Expression Retroviral system
Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential
More informationHepatitis C virus (HCV) has emerged as the major
Hepatitis C Virus Receptor Expression in Normal and Diseased Liver Tissue Gary M. Reynolds, 1 * Helen J. Harris, 2 * Adam Jennings, 2 Ke Hu, 2 Joe Grove, 2 Patricia F. Lalor, 1 David H. Adams, 1 Peter
More informationDynamic Interaction of Stress Granule, DDX3X and IKK-α Mediates Multiple Functions in
Dynamic Interaction of Stress Granule, and Mediates Multiple Functions in Hepatitis C Virus Infection Véronique Pène, Qisheng Li#, Catherine Sodroski, Ching-Sheng Hsu, T. Jake Liang# Liver Diseases Branch,
More informationPRODUCT INFORMATION & MANUAL
PRODUCT INFORMATION & MANUAL 0.4 micron for Overall Exosome Isolation (Cell Media) NBP2-49826 For research use only. Not for diagnostic or therapeutic procedures. www.novusbio.com - P: 303.730.1950 - P:
More informationHepatitis C virus (HCV) is a major cause of
The Postbinding Activity of Scavenger Receptor Class B Type I Mediates Initiation of Hepatitis C Virus Infection and Viral Dissemination Muhammad N. Zahid, 1,2 * Marine Turek, 1,2 * Fei Xiao, 1,2 Viet
More informationLDL Uptake Cell-Based Assay Kit
LDL Uptake Cell-Based Assay Kit Item No. 10011125 www.caymanchem.com Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd Ann Arbor, MI USA TABLE OF CONTENTS GENERAL INFORMATION
More informationNeutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission
JOURNAL OF VIROLOGY, Jan. 2011, p. 596 605 Vol. 85, No. 1 0022-538X/11/$12.00 doi:10.1128/jvi.01592-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Neutralizing Antibody-Resistant
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More informationPrentoe et al., November 1, Hypervariable Region 1 Deletion and Required Adaptive Envelope Mutations Confer Decreased
JVI Accepts, published online ahead of print on 20 November 2013 J. Virol. doi:10.1128/jvi.02017-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Prentoe et al., November 1,
More informationPERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES
71 PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES Harold G. Jensen, Alan J. Parkinson, and L. Vernon Scott* Department of Microbiology & Immunology, University of Oklahoma
More informationEvidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1 Jean-Christophe Meunier*, Ronald E. Engle*, Kristina Faulk*, Ming Zhao,
More informationAdvances in gene encoding proteins of human herpesvirus 6
2009 9 4 3 Journal of Microbes and Infection, September 2009, Vol. 4, No. 3 165 6 1, 2 1., 241000; 2., 210029 : 6 ( HHV-6) DNA, HHV-6 80 100, ( IE) DNA DNA HHV-6 : 6 ; ; Advances in gene encoding proteins
More informationReview. Hepatitis C virus entry into host cells. Cellular and Molecular Life Sciences. F. Helle and J. Dubuisson*
Cell. Mol. Life Sci. 65 (2008) 100 112 1420-682X/08/010100-13 DOI 10.1007/s00018-007-7291-8 Birkhäuser Verlag, Basel, 2007 Cellular and Molecular Life Sciences Review Hepatitis C virus entry into host
More informationSupplementary Information
Supplementary Information Supplementary Figure 1. CD4 + T cell activation and lack of apoptosis after crosslinking with anti-cd3 + anti-cd28 + anti-cd160. (a) Flow cytometry of anti-cd160 (5D.10A11) binding
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationSecondary fluorescent staining of virus antigens by rheumatoid factor and fluorescein-conjugated anti-lgm
Ann. rheum. Dis. (1973), 32, 53 Secondary fluorescent staining of virus antigens by rheumatoid factor and fluorescein-conjugated anti-lgm P. V. SHIRODARIA, K. B. FRASER, AND F. STANFORD From the Department
More informationHepatitis C virus (HCV) is a noncytopathic positive-stranded
Robust hepatitis C virus infection in vitro Jin Zhong*, Pablo Gastaminza*, Guofeng Cheng*, Sharookh Kapadia*, Takanobu Kato, Dennis R. Burton, Stefan F. Wieland*, Susan L. Uprichard*, Takaji Wakita, and
More informationProduct Datasheet. HLA ABC Antibody (W6/32) NB Unit Size: 0.25 mg. Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22
Product Datasheet HLA ABC Antibody (W6/32) NB100-64775 Unit Size: 0.25 mg Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22 Protocols, Publications, Related Products, Reviews, Research
More informationHepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationApplication of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma
Excerpt from MACS&more Vol 8 1/2004 Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma L. Davis Lupo and Salvatore T. Butera HIV and Retrovirology Branch,
More informationGladstone Institutes, University of California (UCSF), San Francisco, USA
Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24 Gag Marianne Gesner, Mekhala Maiti, Robert Grant and Marielle Cavrois * Gladstone Institutes, University of
More informationHepatitis C Virus and Antiviral Drug Resistance
Gut and Liver, Vol. 10, No. 6, November 2016, pp. 890-895 Review Hepatitis C Virus and Antiviral Drug Resistance Seungtaek Kim, Kwang-Hyub Han, and Sang Hoon Ahn Institute of Gastroenterology, Department
More informationSupplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins
Supplementary information inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Takuya Tada, Yanzhao Zhang, Takayoshi Koyama, Minoru Tobiume, Yasuko Tsunetsugu-Yokota, Shoji
More informationAnti-DC-SIGN/CD209 murine monoclonal antibodies
Anti-DC-SIGN/CD209 murine monoclonal antibodies DC-SIGN (DC Specific, ICAM-3 Grabbing, Nonintegrin) / CD209 and L-SIGN (liver/lymph node-specific ICAM-3-grabbing nonintegrin CD299/ DC-SIGNR (DC-SIGN-related
More informationDoctoral Degree Program in Marine Biotechnology, College of Marine Sciences, Doctoral Degree Program in Marine Biotechnology, Academia Sinica, Taipei,
Cyclooxygenase 2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents Chun-Kuang Lin 1,2, Chin-Kai Tseng 3,4, Yu-Hsuan Wu 3,4, Chih-Chuang Liaw 1,5, Chun-
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Hepatoma cell density promotes Claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization Schwarz, AK; Grove, Joseph; Hu, Ke; Mee, Christopher; Balfe, Peter; McKeating, Jane DOI:
More informationBacPAK Baculovirus Rapid Titer Kit
BacPAK Baculovirus Rapid Titer Kit United States/Canada 800.662.2566 Asia Pacific +1.650.919.7300 Europe +33.(0)1.3904.6880 Japan +81.(0)77.543.6116 Cat. No. 631406 PT3153-1 (072213) Clontech Laboratories,
More informationType I Interferon Rapidly Restricts Infectious Hepatitis C Virus Particle Genesis
Type I Interferon Rapidly Restricts Infectious Hepatitis C Virus Particle Genesis Luke W. Meredith, 1 Michelle J. Farquhar, 1 Alexander W. Tarr, 2 and Jane A. McKeating 1,3 Interferon-alpha (IFNa) has
More informationHepatitis C Virus Infection in Phenotypically Distinct Huh7 Cell Lines
Hepatitis C Virus Infection in Phenotypically Distinct Huh7 Cell Lines Bruno Sainz, Jr. 1, Naina Barretto 1, Susan L. Uprichard 1,2 * 1 Department of Medicine, University of Illinois at Chicago, Chicago,
More informationGenomic Alterations Associated with Persistent Infections by Equine Infectious Anaemia Virus, a Retrovirus
J. gen. Virol. (1984), 65, 1395-1399. Printed in Great Britain 1395 Key words: EIA V/retrovirus persistence~antigenic variation/oligonucleotide mapping Genomic Alterations Associated with Persistent Infections
More informationIdentification of Microbes Lecture: 12
Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected
More informationHepatitis C virus (HCV) is an enveloped positive-stranded
Neutralizing antibody response during acute and chronic hepatitis C virus infection C. Logvinoff*, M. E. Major, D. Oldach, S. Heyward, A. Talal, P. Balfe, S. M. Feinstone, H. Alter, C. M. Rice*, and J.
More informationTechnical Bulletin No. 162
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationLongitudinal Studies of Neutralizing Antibody Responses to Rotavirus in Stools and Sera of Children following Severe Rotavirus Gastroenteritis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 1998, p. 897 901 Vol. 5, No. 6 1071-412X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Longitudinal Studies of
More informationLDL Uptake Cell-Based Assay Kit
LDL Uptake Cell-Based Assay Kit Catalog Number KA1327 100 assays Version: 07 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay...
More informationJVI Accepts, published online ahead of print on 23 March 2011 J. Virol. doi: /jvi
JVI Accepts, published online ahead of print on 23 March 2011 J. Virol. doi:10.1128/jvi.02116-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationHepatitis C virus (HCV) is an important
Human Apolipoprotein E Peptides Inhibit Hepatitis C Virus Entry by Blocking Virus Binding Shufeng Liu, 1 Kevin D. McCormick, 1 Wentao Zhao, 2 Ting Zhao, 3,4 Daping Fan, 2 and Tianyi Wang 1 Hepatitis C
More informationHuman HBcAb IgM ELISA kit
Human HBcAb IgM ELISA kit Catalog number: NR-R10163 (96 wells) The kit is designed to qualitatively detect HBcAb IgM in human serum or plasma. FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PURPOSES
More informationSupplementary Material
Supplementary Material Nuclear import of purified HIV-1 Integrase. Integrase remains associated to the RTC throughout the infection process until provirus integration occurs and is therefore one likely
More informationHepatitis C virus (HCV) has frustrated researchers
SCIENCE FRONTIER Hepatitis C Virus Comes Full Circle: Production of Recombinant Infectious Virus in Tissue Culture Jan Martin Berke and Darius Moradpour Hepatitis C virus (HCV) has frustrated researchers
More informationDeterminants for Membrane Association of the Hepatitis C Virus NS2 Protease Domain
JVI Accepts, published online ahead of print on 19 March 2014 J. Virol. doi:10.1128/jvi.00224-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 3 Revised JVI00224-14 Short-Form
More informationMore than 170 million people worldwide are infected
Anti-CD81 Antibodies Can Prevent a Hepatitis C Virus Infection In Vivo Philip Meuleman, 1 Joseph Hesselgesser, 2 Matthew Paulson, 2 Thomas Vanwolleghem, 1 Isabelle Desombere, 1 Hans Reiser, 2 and Geert
More informationThe neutralizing activity of anti-hcv antibodies is modulated by specific ACCEPTED. glycans on the E2 envelope protein
JVI Accepts, published online ahead of print on May 00 J. Virol. doi:0./jvi.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Helle et al.
More informationViral hepatitis. The word hepatitis means inflammation of the liver. There are five main types of viral hepatitis: A, B, C, D, E
Viral hepatitis The word hepatitis means inflammation of the liver There are five main types of viral hepatitis: A, B, C, D, E Hepatitis A and E are typically caused by ingestion of contaminated food or
More informationRalf Wagner Paul-Ehrlich-Institut
www.pei.de Other Assays for the Detection of Neuraminidase (NA)-Specific Antibodies Ralf Wagner Paul-Ehrlich-Institut Overview to presented assays Assay principle based on: Chemical substrates: Protein
More informationMitochondrial Trifunctional Protein (TFP) Protein Quantity Microplate Assay Kit
PROTOCOL Mitochondrial Trifunctional Protein (TFP) Protein Quantity Microplate Assay Kit DESCRIPTION Mitochondrial Trifunctional Protein (TFP) Protein Quantity Microplate Assay Kit Sufficient materials
More informationHuman Cytomegalovirus
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1975, p. 332-336 Copyright ) 1975 American Society for Microbiology Vol. 2, No. 4 Printed in U.S.A. Demonstration of Immunoglobulin G Receptors Induced by Human Cytomegalovirus
More informationLaboratory diagnosis of congenital infections
Laboratory diagnosis of congenital infections Laboratory diagnosis of HSV Direct staining Tzanck test Immunostaining HSV isolation Serology PCR Tzanck test Cell scrape from base of the lesion smear on
More informationRabbit Polyclonal antibody to NFkB p65 (v-rel reticuloendotheliosis viral oncogene homolog A (avian))
Datasheet GeneTex, Inc : Toll Free 1-877-GeneTex (1-877-436-3839) Fax:1-949-309-2888 info@genetex.com GeneTex International Corporation : Tel:886-3-6208988 Fax:886-3-6208989 infoasia@genetex.com Date :
More informationVirology 433 (2012) Contents lists available at SciVerse ScienceDirect. Virology. journal homepage:
Virology 433 (2012) 462 470 Contents lists available at SciVerse ScienceDirect Virology journal homepage: www.elsevier.com/locate/yviro The specific infectivity of hepatitis C virus changes through its
More informationThis is a pre- or post-print of an article published in Steinmann, E., Pietschmann, T. Cell culture systems for hepatitis C virus (2013) Current
This is a pre- or post-print of an article published in Steinmann, E., Pietschmann, T. Cell culture systems for hepatitis C virus (2013) Current Topics in Microbiology and Immunology, 369, pp. 17-48. Chapter
More informationNOTES. Nonhepatic Cell Lines HeLa and 293 Support Efficient Replication of the Hepatitis C Virus Genotype 2a Subgenomic Replicon
JOURNAL OF VIROLOGY, Jan. 2005, p. 592 596 Vol. 79, No. 1 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.1.592 596.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. NOTES Nonhepatic
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationMutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies
GASTROENTEROLOGY 2012;143:223 233 Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies ISABEL FOFANA,*, SAMIRA FAFI KREMER,*,, PATRIC CAROLLA,*,
More informationVIROLOGY. Engineering Viral Genomes: Retrovirus Vectors
VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar
More informationSalivary mucinmuc5b inhibits HIV-1 subtype C in an in vitro pseudoviral assay
Salivary mucinmuc5b inhibits HIV-1 subtype C in an in vitro pseudoviral assay Julia Peacocke, Zoe Lotz, Jeffrey R Dorfman 1, Delawir Kahn, Paul Roux 2 and Anwar S Mall* Division of General Surgery and
More informationThe Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells
JOURNAL OF VIROLOGY, Jan. 2007, p. 588 598 Vol. 81, No. 2 0022-538X/07/$08.00 0 doi:10.1128/jvi.01534-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. The Level of CD81 Cell Surface
More informationPrimary hepatocytes as targets for Hepatitis C virus replication
Journal of Viral Hepatitis, 2008, 15, 849 854 doi:10.1111/j.1365-2893.2008.01051.x REVIEW Primary hepatocytes as targets for Hepatitis C virus replication M. J. Farquhar and J. A. McKeating Hepatitis C
More information